Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Answer to a Commentary on "Tango for treatment of motor and non-motor manifestations in Parkinson's disease: A randomized control study".

Rios Romenets S, Fereshtehnejad SM, Postuma R.

Complement Ther Med. 2018 Oct;40:258-259. doi: 10.1016/j.ctim.2017.11.005. Epub 2017 Nov 20. No abstract available.

PMID:
30219464
2.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27431. [Epub ahead of print]

PMID:
30145841
3.

Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D.

Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27362. [Epub ahead of print]

PMID:
30145797
4.

Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan.

Rios-Romenets S, Acosta-Baena N, Lopez L, Madrigal-Zapata L, Street H, Jakimovich L, Langbaum JB, Cho W, Reiman EM, Tariot PN, Lopera F.

Alzheimers Dement (N Y). 2018 Jul 14;4:283-287. doi: 10.1016/j.trci.2018.06.010. eCollection 2018.

5.

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.

Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, Rios-Romenets S, Giraldo M, Acosta N, Tobon C, Ramos C, Espinosa A, Cho W, Ward M, Clayton D, Friesenhahn M, Mackey H, Honigberg L, Sanabria Bohorquez S, Chen K, Walsh T, Langlois C, Reiman EM; Alzheimer's Prevention Initiative.

Alzheimers Dement (N Y). 2018 Mar 8;4:150-160. doi: 10.1016/j.trci.2018.02.002. eCollection 2018.

6.

Office-Based Screening for Dementia in Parkinson Disease: The Montreal Parkinson Risk of Dementia Scale in 4 Longitudinal Cohorts.

Dawson BK, Fereshtehnejad SM, Anang JBM, Nomura T, Rios-Romenets S, Nakashima K, Gagnon JF, Postuma RB.

JAMA Neurol. 2018 Jun 1;75(6):704-710. doi: 10.1001/jamaneurol.2018.0254.

PMID:
29582054
7.

The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.

Rios-Romenets S, Giraldo-Chica M, López H, Piedrahita F, Ramos C, Acosta-Baena N, Muñoz C, Ospina P, Tobón C, Cho W, Ward M, Langbaum JB, Tariot PN, Reiman EM, Lopera F.

J Prev Alzheimers Dis. 2018;5(1):49-54. doi: 10.14283/jpad.2017.44.

8.

Tango for treatment of motor and non-motor manifestations in Parkinson's disease: a randomized control study.

Rios Romenets S, Anang J, Fereshtehnejad SM, Pelletier A, Postuma R.

Complement Ther Med. 2015 Apr;23(2):175-84. doi: 10.1016/j.ctim.2015.01.015. Epub 2015 Feb 9.

PMID:
25847555
9.

Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation.

Kosik KS, Muñoz C, Lopez L, Arcila ML, García G, Madrigal L, Moreno S, Ríos Romenets S, Lopez H, Gutierrez M, Langbaum JB, Cho W, Suliman S, Tariot PN, Ho C, Reiman EM, Lopera F.

Neurology. 2015 Jan 13;84(2):206-8. doi: 10.1212/WNL.0000000000001130. Epub 2014 Dec 3. No abstract available.

10.

Treatment of restless legs syndrome.

Rios Romenets S, Postuma RB.

Curr Treat Options Neurol. 2013 Aug;15(4):396-409. doi: 10.1007/s11940-013-0241-x.

PMID:
23703310
11.

Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.

Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, Postuma RB.

Parkinsonism Relat Disord. 2013 Jul;19(7):670-5. doi: 10.1016/j.parkreldis.2013.03.003. Epub 2013 Apr 2.

PMID:
23561946
12.

Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease.

Rios Romenets S, Dauvilliers Y, Cochen De Cock V, Carlander B, Bayard S, Galatas C, Wolfson C, Postuma RB.

Parkinsonism Relat Disord. 2013 Jan;19(1):92-4. doi: 10.1016/j.parkreldis.2012.07.019. Epub 2012 Aug 24.

PMID:
22922159
13.

Caffeine for treatment of Parkinson disease: a randomized controlled trial.

Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, Chuang R, Shah B.

Neurology. 2012 Aug 14;79(7):651-8. doi: 10.1212/WNL.0b013e318263570d. Epub 2012 Aug 1. Erratum in: Neurology. 2012 Oct 16;79(16):1744.

14.

Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study.

Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendette M, Rios Romenets S, Panisset M, Gagnon JF.

Mov Disord. 2012 May;27(6):720-6. doi: 10.1002/mds.24939. Epub 2012 Feb 9.

PMID:
22322798
15.

[Pharmacotherapy of the cognitive sequelae secondary to traumatic brain injury].

Riós-Romenets S, Castaño-Monsalve B, Bernabeu-Guitart M.

Rev Neurol. 2007 Nov 1-15;45(9):563-70. Review. Spanish.

16.

[Semantic dementia: a case report].

Ríos-Romenets S, Tirado V, Arbeláez A, Ríos A, Lopera F.

Rev Neurol. 2005 Feb 16-28;40(4):253-4. Spanish. No abstract available.

Supplemental Content

Loading ...
Support Center